To compare tumor growth curves, the AUC by day 17 was assessed and demonstrated significant tumor growth reduction when anti–PD-1 was combined with either anti-VEGF or lenvatinib, P < 0.001 and < 0.0001, respectively, compared with control (Supplemental Figure 2). This evidence concerns the gene VEGFA and neoplasm.